ARTICLE | Clinical News

BioTime reports additional data for Renevia facial lipoatrophy device

October 6, 2017 7:37 PM UTC

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy characterized by the pathological loss of body fat from under the skin. Patients were transplanted in each side of the face with Renevia. After transplant, patients retained an average of 82% of their hemifacial volume at 9 months (n=21), 70% at 12 months (n=15) and 64% at 18 months (n=5) compared to patients who delayed treatment. Change in hemifacial volume was measured by 3D photographic volumetric assessment.

BioTime previously reported that patients treated with Renevia (n=28) retained 100% of their hemifacial volume at 6 months, the primary endpoint...

BCIQ Company Profiles

Lineage Cell Therapeutics Inc.